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Despite many advances, our understanding of the involvement of prodynorphin systems in the devel-
opment of neuropathic pain is not fully understood. Recent studies suggest an important role of
neuroeglial interactions in the dynorphin effects associated with neuropathic pain conditions. Our
studies show that minocycline reduced prodynorphin mRNA levels that were previously elevated in the
spinal and/or dorsal root ganglia (DRG) following sciatic nerve injury. The repeated intrathecal admin-
istration of minocycline enhanced the analgesic effects of low-dose dynorphin (0.15 nmol) and U50,488H
(25e100 nmol) and prevented the development of ﬂaccid paralysis following high-dose dynorphin
administration (15 nmol), suggesting a neuroprotective effect. Minocycline reverts the expression of IL-
1b and IL-6 mRNA within the spinal cord and IL-1b mRNA in DRG, which was elevated following
intrathecal administration of dynorphin (15 nmol). These results suggest an important role of these
proinﬂammatory cytokines in the development of the neurotoxic effects of dynorphin. Similar to min-
ocycline, a selective inhibitor of MMP-9 (MMP-9 levels are reduced by minocycline) exerts an analgesic
effect in behavioral studies, and its administration prevents the occurrence of ﬂaccid paralysis caused by
high-dose dynorphin administration (15 nmol). In conclusion, our results underline the importance of
neuroeglial interactions as evidenced by the involvement of IL-1b and IL-6 and the minocycline effect in
dynorphin-induced toxicity, which suggests that drugs that alter the prodynorphin system could be used
to better control neuropathic pain.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Endogenous opioid systems are one of the most important
systems that control nociception. Opioids have been used for the
treatment of pain due to their analgesic effects (Przewlocki and
Przewlocka, 2005). The role of dynorphin in the development of
chronic pain is particularly interesting, but it has not been fully
elucidated. Numerous studies note the non-opioid effects of
dynorphin in neuropathic pain (Draisci et al., 1991; Laughlin et al.,
1997; Obara et al., 2003; Mika et al., 2011). Prodynorphin level in
the lumbar spinal region increases following peripheral nerve
injury, as demonstrated for the ﬁrst time in Northern blot assays
(Faden et al., 1985; Przewłocki et al., 1988) and later using in situ
hybridization (Obara et al., 2003). Dynorphin exerts analgesic ef-
fects via the KOP receptor (Walker et al., 1982; Przewłocki et al.,Polish Academy of Sciences,
43 Krakow, Poland. Tel.: þ48
a272@onet.eu (J. Mika).
Ltd. This is an open access article u1983; Vanderah et al., 1996; Laughlin et al., 1997; Jolivalt et al.,
2006). However, the intrathecal administration of dynorphin at
high doses enhances the release of stimulatory neurotransmitters
and cytokine synthesis and induces ﬂaccid paralysis (Faden, 1990;
Dubner and Ruda, 1992). These effects are not inhibited following
the administration of an opioid receptor antagonist, naloxone, but
they are reduced following the earlier administration of an NMDA
receptor antagonist, MK-801 (Vanderah et al., 1996; Laughlin et al.,
1997). The effects of dynorphin are bimodal; the administration of
high doses of dynorphin enhances intracellular levels of Ca2þ via
the simultaneous activation of NMDA and KOP receptors, but the
administration of low doses activates only KOP receptors (Laughlin
et al., 1997; Hu et al., 1998). Whether microglia, which are strongly
activated during the development of neuropathic pain, impact the
effects of dynorphin is unknown. Dynorphin is synthesized by
neurons (Sasek et al., 1984), oligodendrocytes (Knapp et al., 2001)
but not by astrocytes (Shinoda et al., 1989). Machelska (2007)
revealed that various immune cells, including lymphocytes and
macrophages, may produce dynorphin, which plays an important
role in the regulation of cellular and humoral immune responsesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
E. Rojewska et al. / Neuropharmacology 86 (2014) 301e310302and affects cytokine production. During neuropathy, neurons and
glia exchange signals through cytokines (Mika et al., 2008; Austin
and Moalem-Taylor, 2010). The activation of p38MAPK triggers
the production of pronociceptive and antinociceptive cytokines,
which play an important role in nociception (DeLeo and Yezierski,
2001; Mika et al., 2008, 2013;). Neuropathic pain develops due to
a disturbance in the equilibrium between algesic and analgesic
cytokines, therefore, for our study we chose two pronociceptive (IL-
1beta, IL-6) and two antinociceptive (IL-1alpha, IL-10) cytokines.
Minocycline which is a tetracycline derivative with pleiotropic
biological effects inhibits spinal p38MAPK activation in microglia
(Hains and Waxman, 2006), decreases proinﬂammatory cytokine
levels and attenuates neuropathic pain development after nerve
injury. Some authors show that minocycline can inﬂuence neurons
in cultures (Gieseler et al., 2009; Mishra et al., 2009), others that
reduces pain via the inhibition of Ca2þ and Naþ currents in sensory
neurons (Kim et al., 2011; Liu et al., 2013). It was also documented
that minocycline inhibited MMP-9 activity, which is one of the
targets of this drug. In 2008, Kawasaki et al. demonstrated the
crucial role of MMP-9 in the development of neuropathic pain.
Moreover, MMP-9 is one of the targets of minocycline. It was
interesting to check whether blocking of MMP-9 will trigger the
same effect on the toxic dynorphin action as that caused by min-
ocycline. Our previously published studies suggest that intraperi-
toneal minocycline treatment parallels the inhibition of C1q-
positive cells (microglia, monocytes and polymorphonuclear leu-
kocytes) and decreases the nerve injury-induced increase of the
prodynorphin mRNA level (Mika et al., 2010).
An understanding of the molecular mechanisms of the prody-
norphin system in neuropathic pain, with particular focus on the
interactions between microglia and neurons, should improve the
possibility of reducing the toxic effects of dynorphin in neuropathic
pain. Therefore, the goal of our study was to pharmacologically
modulate the prodynorphin system in neuropathic pain. First, the
aim of our studies was to determine the role of microglia in the
effects of dynorphin using minocycline, an inhibitor of microglial
activation. We examined the effects of repeated intrathecal mino-
cycline administration on the effects of U50,488H, dynorphin and
norBNI, k-opioid (KOP) receptor ligands, during neuropathic pain.
Second, we used qRT-PCR to determine changes in the biosynthesis
of C1q, MMP-9, PDYN and interleukins (antinociceptive IL-1a, IL-
10; pronociceptive IL-1b, IL-6) under neuropathic pain and/or
following intrathecal dynorphin administration. Third, we per-
formed repeated intrathecal administrations of MMP-9 inhibitor I
and examined the inﬂuence of this inhibitor on dynorphin-induced
toxicity during neuropathic pain.2. Materials and methods
2.1. Animals
Male Wistar rats (300e350 g) from Charles River (Hamburg, Germany) were
housed in cages lined with sawdust under a standard 12/12 h light/dark cycle (lights
on at 08:00 h) with food and water ad libitum. All efforts were made to minimize
animal suffering and to reduce the number of animals used. All experiments were
performed according to the recommendations of the International Association for
the Study of Pain (IASP) (Zimmermann, 1983) and the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. The local Bioethics Committee
approved all experiments (Krakow, Poland).2.2. Intrathecal catheter implantation
The rats were chronically implanted with intrathecal (i.t.) catheters according to
the methods of Yaksh and Rudy (1976) under pentobarbital anesthesia (60 mg/kg;
i.p.). The catheter (PE 10, INTRAMEDIC, Clay Adams, Becton Dickinson and Company,
Rutherford, NJ, USA) was rinsed via immersion in 70% ethanol and fully ﬂushed with
sterile water prior to insertion. The catheter was carefully introduced through the
atlanto-occipital membrane and advanced to the subarachnoid space at the rostral
level of the spinal cord lumbar enlargement (L4eL6).2.3. Chronic constriction injury
Chronic constriction injury (CCI) was produced according to the methods of
Bennett and Xie (1988). The right sciatic nerve was exposed under sodium pento-
barbital anesthesia (60 mg/kg; i.p.). Four ligatures (4/0 silk) were made around the
nerve distal to the sciatic notch with 1-mm spacing until a brief twitch in the
respective hind limb was observed. All rats after surgery developed long-lasting
neuropathic pain symptoms, such as allodynia and hyperalgesia. CCI of the sciatic
nerve was performed ﬁve days after catheter implantation.
2.4. Drug administration
Minocycline hydrochloride (MC; 60 mg/5 ml; Sigma, Schnelldorf, Germany) was
dissolved in water for injections and administered preemptively via i.t. injection 16
and 1 h before CCI and then once daily for 7 days as described previously (Mika
et al., 2007). This administration schedule was used because systemic microglia
inhibitors attenuate the activation of microglia more efﬁciently when the inhibitor
is injected before injury (Raghavendra et al., 2003; Ledeboer et al., 2005). The
control groups received vehicle (water for injection) according to the same
schedule (Scheme 1). All drugs were injected i.t. at a volume of 5 ml, followed by an
injection of 10 ml of bidistilled water to ﬂush the catheter. Dynorphin A(1e17) (DYN;
0.15 and 15 nmol/5 ml; Tocris, Warsaw, Poland) was dissolved in water for injections
and administered via i.t. injection 7 days after CCI (Laughlin et al., 2000; Wang
et al., 2009). U50,488 hydrochloride (U50,488H; 25 and 100 nmol/5 ml; U50;
Tocris, Warsaw, Poland) was dissolved in water for injections and administered via
i.t. injection 7 days after CCI (Omana et al., 1994). MMP-9 inhibitor I (MMP-9 INH.I,
5 mg/5 ml, Merc Millipore, Warsaw, Poland) was dissolved in 50% DMSO and
administered preemptively via i.t. injection 16 and 1 h before CCI and then once
daily for 7 days or as a single injection 7 days after CCI (Kawasaki et al., 2008). nor-
Binaltorphimine dihydrochloride (norBNI; 6.8 and 13.6 nmol/5 ml; Tocris, Warsaw,
Poland) was dissolved in water for injections and administered via i.t. injection 7
days after CCI. The control groups received vehicle (water for injections or DMSO)
according to the same schedule.
2.5. Behavioral tests
2.5.1. Tactile allodynia (von Frey test)
Allodynia was measured using electronic von Frey apparatus (Dynamic Plantar
Anesthesiometer Cat. No. 37400, Ugo Basile, Italy). Animals were placed in plastic
cages with wire net ﬂoors 5 min before the experiment. The von Frey ﬁlament was
applied to the midplantar surface of the hind paw, and measurements were taken
automatically as described previously (Mika et al., 2007, 2010; Makuch et al., 2013).
We tested the ipsilateral paw two times in 3-min intervals, and the mean value was
calculated. The strengths of the von Frey stimuli used in our experiments were up to
26 g. There was almost no response in naïve animals to the highest strengths.
2.5.2. Thermal hyperalgesia (cold plate test)
Hyperalgesia was assessed using the cold plate test (Cold/Hot Plate Analgesia
Meter No. 05044, Columbus Instruments, USA) as described previously (Mika et al.,
2007, 2010; Makuch et al., 2013). The temperature of the cold plate was maintained
at 5 C, and the cut-off latency was 30 s. The animals were placed on the cold plate,
and the time until a lifting of the hind paw occurred was recorded. The reaction of
the ﬁrst hind paw to be lifted in the naïve rat group was measured. The injured paw
was the ﬁrst to react in all cases.
2.6. Biochemical tests
2.6.1. Tissue collection and RNA isolation
Ipsilateral fragments of the dorsal part of the lumbar (L4eL6) spinal cord and the
DRG (L4eL6) were removed immediately after decapitation on day 7 following CCI,
4 h after MC administration. The tissue samples were placed in individual tubes with
the RNAlater tissue storage reagent (Qiagen Inc., Valencia, USA) and stored at70 C
for RNA isolation. Total RNA was extracted using TRIzol reagent (Invitrogen) as
described previously (Chomczynski and Sacchi, 1987). The RNA concentration was
measured using a NanoDrop ND-1000 Spectrometer (ND-1000, NanoDrop Tech-
nologies, Montchanin, DE), and RNA quality was determined using chip-based
capillary electrophoresis with an RNA 6000 Nano LabChip Kit and Agilent Bio-
analyzer 2100 (Agilent) according to the manufacturer's instructions.
2.6.2. Quantitative PCR
Reverse transcription was performed on 2 mg of total RNA using Omniscript
reverse transcriptase (Qiagen Inc.) at 37 C for 60 min. RT reactions were performed
in the presence of an RNAse inhibitor (rRNAsin, Promega) and oligo (dT16) primer
(Qiagen Inc.). cDNAwas diluted 1:10with H2O, and ~50 ng of cDNA synthesized from
the total RNA template from individual animals was used for each quantitative Real-
Time PCR (RT-qPCR) reaction. RT-qPCR was performed using Assay-On-Demand
TaqMan probes according to the manufacturer's protocol (Applied Biosystems)
and run in an iCycler device (BioRad, Hercules). A standard dilution curve deter-
mined the ampliﬁcation efﬁciency for each assay. The following TaqManprimers and
probes were used: Rn01527838_g1 (HPRT, hypoxanthine guanine rat hypoxanthine
guanine phosphoribosyl transferase); Rn00570480_m1 (C1q, complement
Scheme 1. Drug administration.
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(PDYN, prodynorphin); Rn00566700_m1 (IL-1a, interleukin 1alpha);
Rn00563409_m1 (IL-10, interleukin 10); Rn00580432_m1 (IL-1b, interleukin 1beta)
and Rn00561420_m1 (IL-6, interleukin 6). A standard dilution curve determined the
ampliﬁcation efﬁciency for each assay (between 1.7 and 2). The cycle threshold
values were calculated automatically by iCycler IQ 3.0 software using the default
parameters. RNA abundancewas calculated as 2-(threshold cycle). HPRT transcript levelsScheme 2. Dynorphin may play a physiological role and exert antinociceptive effects via t
mechanism e.g. activation of the NMDA receptor (A). Minocycline decreased the activatio
dynorphin-induced IL-1b and IL-6mRNA (B). Our research enriches and systematizes our kn
and non-opioid action of this peptide. Dynorphin may play a physiological role via the opioi
effects. Dynorphin also induces pathological effects via activation of the NMDA receptor to p
2003) (Scheme 2a). The administration of KOP receptor antagonists norbinaltorphimine (nor
(Obara et al., 2003). The potentiation of allodynia after norBNI or GNTI administration was in
et al., 2003). The present studies suggest that neurons and microglia are involved in these ef
2012). High doses of DYN induce the activation of NMDARs (Obara et al., 2003), causing
synthesis of pronociceptive cytokines, such as IL-1b and IL-6. Duarte et al. (2012) sugges
mechanism of minocycline. MMP-9 induces neuropathic pain through IL-1b cleavage and m
paralysis. We have shown that minocycline decreased the activation of microglia and the leve
and IL-6 mRNA levels (Scheme 2b).do not signiﬁcantly change in rats exposed to CCI (Mika et al., 2010), and therefore,
this transcript served as an adequate housekeeping gene.
2.7. Data analysis
All graphs and analyses were prepared using GraphPad Prism (version 5.0). The
behavioral data are presented in grams and seconds as means ± SEM, and eachhe opioid receptor and induce pathological and pronociceptive effects via non-opioid
n of microglia and the levels of MMP-9, IL-1b and IL-6 mRNA after nerve injury and
owledge of the actions of dynorphin and adds new facts to our knowledge of the opioid
d receptor (Przewłocki et al., 1983; Stevens and Yaksh, 1986), and it has antinociceptive
roduce pronociceptive effects (Vanderah et al., 1996; Laughlin et al., 1997; Obara et al.,
BNI) and 50-guanidinonaltrindole (GNTI) enhanced allodynia after sciatic nerve ligation
hibited by the earlier administration of ketamine, an NMDA receptor antagonist (Obara
fects (Scheme 2b). KOP and NMDA receptors induce p38MAPK activation (Lemos et al.,
the activation of p38MAPK. These results suggest that these mechanisms induce the
t that the regulation of MMP-9 is via the p38MAPK pathway, which can also be the
icroglial activation (Scheme 2a). Notably, minocycline administration prevented ﬂaccid
ls ofMMP-9, IL-1b and IL-6mRNA after nerve injury and DYN-induced increase in IL-1b
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one-way analysis of variance (ANOVA). ***p < 0.001 indicates a signiﬁcant difference
marked only between control (naïve rats) and vehicle-treated CCI-exposed rats;
#p < 0.05, ##p < 0.01 and ###p < 0.001 indicate a signiﬁcant difference vs. vehicle-
treated CCI-exposed rats; &p < 0.05 and &&&p < 0.001 indicate a signiﬁcant differ-
ence vs.minocycline and MMP-9 inhibitor I-treated CCI-exposed rats; and ^p < 0.05
and ^^ ^p < 0.001 indicate a signiﬁcant difference vs. KOP-receptor ligand-treated CCI-
exposed rats.
The results of qRT-PCR are presented as fold changes compared to controls
(naive rats), and the results were calculated for the ipsilateral sides of the spinal
cords and DRG of CCI-exposed rats. The quantitative qPCR analysis data are pre-
sented as means ± SEM, which represent normalized averages derived from the
threshold cycle in qPCR from 8 to 10 samples for each group. Inter-group differences
were analyzed using an ANOVA, followed by Bonferroni's repeated comparison test.
*p < 0.05 and ***p < 0.001 indicates a signiﬁcant difference marked only between
control (naïve rats) and vehicle-treated CCI-exposed rats; #p < 0.05, ##p < 0.01 and
###p < 0.001 indicate a signiﬁcant difference vs. vehicle-treated CCI-exposed rats;
&&p < 0.01 and &&&p < 0.001 indicate a signiﬁcant difference vs.minocycline-treated
CCI-exposed rats; and ^p < 0.05 and ^^ ^p < 0.001 indicate a signiﬁcant difference vs.
dynorphin A(1e17)-treated CCI-exposed rats.
3. Results
3.1. Effects of minocycline and dynorphin A(1e17) administration on
C1q, MMP-9 and PDYN mRNA levels in the spinal cord and DRG of
rats 7 days after CCI
The expression of complement component 1, q subcomponent
(C1q), metalloproteinase 9 (MMP-9) and prodynorphin (PDYN)
mRNA in the spinal cord and DRGwas determined using qRT-PCR. A
720% increase in the mRNA of C1q was observed in the spinal cord
after CCI, and a 440% increase was observed in the DRG. Minocy-
cline (60 mg/5 ml, i.t.) signiﬁcantly diminished the injury-induced
increase in C1q mRNA levels in the spinal cord and DRG. No ef-
fects of a single administration of DYN (15 nmol) on the elevated
C1q mRNA level following CCI were observed in either structure. A
single dose of DYN (15 nmol) administered to MC-treated rats did
not inﬂuence C1q mRNA level as compared to vehicle-treated CCI-
exposed rats in the spinal cord or DRG (Table 1).
A 430% strong upregulation of the MMP-9 mRNA level was
detected in the spinal cord after CCI, and a 50% increase was
observed in the DRG. Minocycline signiﬁcantly diminished the
injury-induced increase in the MMP-9 mRNA level in the spinal
cord from 430% to 50%). Minocycline did not alter MMP-9 mRNA
levels in the DRG (Table 1).
A single administration of DYN (15 nmol) had no effect on the
injury-induced changes inMMP-9mRNA expression in either of theTable 1
The effect of repeated intrathecal minocycline administration (MC, 60 mg/5 ml, 16 and 1 h b
on the changes in the expression of themRNA of C1q, metalloproteinase-9 (MMP-9) and p
spinal cord and DRG. The values were standardized against HPRT. The results are presented
Bonferroni's Multiple Comparison Test: *p < 0.05, ***p < 0.001 Naive vs. V þ V CCI-expose
MC þ V and MC þ DYN CCI-exposed rats; ^p < 0.05, ^^ ^p < 0.001 differences between V þtested structures. In animals receiving repeated doses of minocy-
cline, the increase in MMP-9 mRNA expression in the spinal cord
following DYN administration was lower than that following
administration of DYN alone. However, no changes were demon-
strated in the DRG (Table 1).
A strong increase in PDYN mRNA, amounting to 2680%, was
observed in the spinal cord following sciatic nerve ligation, and a
1380% increase was observed in the DRG. Intrathecal minocycline
signiﬁcantly diminished the injury-induced increase in PDYN
mRNA from 2680% to 850% in the spinal cord, but no signiﬁcant
effect of minocycline was observed in the DRG (Table 1).
We have shown that minocycline inhibits the activation of
microglia and MMP-9, and signiﬁcantly inhibits injury-induced
increase in PDYN expression, therefore, in the next experiment
we checked whether the nociceptive effect of kappa receptor li-
gands is altered by minocycline treatment of CCI-exposed rats.3.2. Effect of repeated minocycline administration on the effects of
norBNI, U50,488 and dynorphin A(1e17) after administration in rats
7 days after CCI
All CCI-exposed rats developed neuropathic pain symptoms,
such as allodynia or hyperalgesia. The strong allodynia and
hyperalgesia was already observed on the third day after CCI (data
not shown). The reaction to the mechanical stimulus (von Frey test)
in control rats was observed at 26.0 g ± 0.7, and the reaction to low
temperature was observed after 27.3 s ± 2.4 (cold plate test). Re-
ductions in pain thresholds after CCI were observed in the von Frey
test and the cold plate test and minocycline (MC, 60 mg/5 ml, i.t.)
diminished the allodynia (Fig. 1A, C, E, G, I, K) and hyperalgesia
(Fig. 1B, D, F, H, J, L).
norBNI was i.t. administered at two doses: 6.8 nmol and
13.6 nmol 30 min after the last injection of minocycline. The lower
dose (6.8 nmol) had no effect on allodynia (14.3 g ± 0.6 vs.
13.6 g ± 0.5; Fig. 1A) but enhanced hyperalgesia (8.0 s ± 0.7 vs.
4.9 s ± 0.8; Fig. 1B). The high doses of norBNI (13.6 nmol) enhanced
both allodynia (14.3 g ± 0.6 vs.11.3 g ± 0.6; Fig.1C) and hyperalgesia
(8.0 s ± 0.7 vs. 5.0 s ± 0.6; Fig. 1D). The analgesic effect of mino-
cycline remained unchanged following low and high doses of
norBNI.
U50,488H was i.t. administered at two doses: 25 nmol and
100 nmol 30 min after last injection of minocycline. The lower dose
(25 nmol) had an analgesic effect in the von Frey test (12.5 g ± 0.4efore sciatic nerve injury and then once daily for 7 days) and dynorphin A(1e17) (DYN)
rodynorphin (PDYN) on day 7 following sciatic nerve ligation (CCI) as measured in the
as fold changes of control (Naïve). Inter-group differences were analyzed by ANOVA
d rats; #p < 0.05, ###p < 0.001 vs. V þ V CCI-exposed; &&p < 0.01 differences between
DYN and MC þ DYN CCI-exposed rats. Vehicle (V; water for injection).
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test (7.3 s ± 0.7 vs. 10.0 s ± 1.8; Fig. 1F). The analgesic effect of
minocycline remained unchanged following low dose U50,488H
administration, as demonstrated in von Frey's test (17.8 g ± 0.7 vs.
17.7 g ± 0.7; Fig. 1E) and the cold plate test (12.7 s ± 1.8 vs.
12.5 s ± 3.0; Fig. 1F). The high dose (100 nmol) had an analgesic
effect in the von Frey (12.5 g ± 0.4 vs.14.9 g ± 0.4; Fig.1G), cold plate
test (7.3 s ± 0.7 vs.13.4 s ± 2.8; Fig.1H). The administration of higher
doses of U50,488H to animals previously receiving minocycline
enhanced the analgesic effect in von Frey's test (Fig. 1G) but not in
the cold plate test (Fig. 1H).
DYN was i.t. administered at two doses: 0.15 nmol and 15 nmol.
Analgesic effects were demonstrated 30 min following the
administration of the lower dose of DYN (0.15 nmol) in the von Frey
(11.0 g ± 0.4 vs. 19.3g ± 0.8; Fig. 1I) and cold plate (6.3 s ± 0.5 vs.
17.4 s ± 1.0) tests (Fig. 1J). Additionally, the DYN antinociceptive
effect, but not paralysis, was blocked by norBNI (13.6 nmol)
administration (Table 2). Additionally, the DYN antinociceptive ef-
fect, but not paralysis, was blocked by norBNI (13.6 nmol) admin-
istration (Table 2). In animals previously receiving minocycline, we
observed enhanced analgesic effects of low-dose DYN(1-17)
(0.15 nmol) on hyperalgesia (Fig. 1J). High doses of DYN (15 nmol)
caused ﬂaccid paralysis, which made measurement of hypersensi-
tivity to mechanical (Fig. 1K) and thermal stimuli (Fig. 1L) impos-
sible. Minocycline prevented the occurrence of ﬂaccid paralysis
following high dose DYN administration (Fig. 1K, L).
The results indicate that administration of 15 nmol of DYN
causes neurotoxic effects resulting in ﬂaccid paralysis. Blocking
these neurotoxic effects by minocycline suggests an involvement of
nociceptive factors and, therefore, in next experiments we checked
the changes in the well known pro- and antinociceptive
interleukins.
3.3. Effect of minocycline and dynorphin A(1e17) administration on
mRNA levels of antinociceptive IL-1a and IL-10 in the spinal cord
and DRG in rats 7 days after CCI
The qRT-PCR method revealed no changes in the expression of
anti-inﬂammatory IL-1a and IL-10 mRNA in the spinal cord
following CCI (Fig. 2A, C). In contrast, a 4100% upregulation of IL-1a
mRNA was observed in the DRG (1.0 ± 0.05 vs. 42.0 ± 5.1; Fig. 2B),
while IL-10 mRNA expression increased by 400% (1.0 ± 0.1 vs.
5.0 ± 1.8; Fig. 2D).
No signiﬁcant effects on IL-1a and IL-10 mRNA levels in either
tested structure were observed after minocycline administration or
following a single DYN administration (15 nmol/5 ml; Fig. 2A, B, C,
D). Additionally, DYN administration previously receiving repeated
doses of minocycline had no effect on the changes in IL-1a (Fig. 2A,
B) and IL-10 mRNA (Fig. 2C, D) levels in the spinal cord and in DRG.
Our results indicate that after minocycline administration, a single
DYN dose does not inﬂuence the level of this antinociceptive
interleukin under neuropathic pain.
3.4. Effect of minocycline and dynorphin A(1e17) administration on
the mRNA levels of pronociceptive interleukins IL-1b and IL-6 in the
spinal cord and DRG in rats 7 days after CCI
The upregulation of IL-1b mRNA, amounting to 310%, was
observed in the spinal cord (1.0 ± 0.2 vs. 4.1 ± 0.2; Fig. 2E), and a
130% increase of IL-1bmRNAwas detected in the DRG (1.0 ± 0.2 vs.
2.3 ± 0.6; Fig. 2F) following CCI. A strong upregulation of 710% for
IL-6 mRNA was observed in the spinal cord (1.0 ± 0.1 vs. 8.1 ± 2.0;
Fig. 2G), together with a very strong (8900%) increase in the DRG
(1.0 ± 0.3 vs. 90.1 ± 6.5; Fig. 2H). Minocycline signiﬁcantly dimin-
ished the injury-induced increase in IL-1bmRNA in the spinal cord(4.1 ± 0.2 vs. 2.6 ± 0.3; Fig. 2E) but not in the DRG (2.3 ± 0.6 vs.
1.7 ± 0.6; Fig. 2F). The expression of IL-6mRNA in the spinal cord in
animals receiving minocycline was lower compared to animals
following nerve injury (8.1 ± 2.0 vs. 3.7 ± 1.9; Fig. 2G). The
expression of IL-6 mRNA in the DRG was lower (4700% instead of
8900%) after minocycline administration (90.1 ± 6.5 vs. 47.6 ± 4.6;
Fig. 2H).
A single administration of DYN (15 nmol/5 ml) resulted in a
strong (1730%) upregulation of IL-1bmRNA (4.1 ± 0.2 vs. 18.3 ± 3.0)
in the spinal cord (Fig. 2E) and a 630% increase in the DRG (2.3 ± 0.6
vs. 7.3 ± 2.0; Fig. 2F). A strong increase of 4560% in the expression of
IL-6mRNAwas also observed within the spinal cord following DYN
administration (8.1 ± 2.0 vs. 46.6 ± 15.1; Fig. 2G), but no effect of
DYN on IL-6 mRNA levels was observed in the DRG (Fig. 2H). In
animals previously receiving repeated doses of minocycline, DYN
administration was associated with a lower change in spinal IL-1b
mRNA expression than DYN administration alone, from 1730% to
490% (18.3 ± 3.0 vs. 5.9 ± 1.1; Fig. 2E) and from 630% to 260% in the
DRG (7.3 ± 2.0 vs. 3.6 ± 0.6; Fig. 2F). In addition, downregulation of
mRNA IL-6 from 4560% to 260% was demonstrated in the spinal
cord (46.6 ± 15.1 vs. 3.6 ± 1.4; Fig. 2G), but no effects on the
expression within the DRG were observed (Fig. 2H).
Our results indicate that minocycline inﬂuences the level of the
examined pronociceptive interleukins under neuropathic pain, and
that IL-1beta and IL-6 seems to play an important role in DYN-
induced neurotoxicity.
3.5. Effect of repeated metalloproteinase-9 inhibitor (MMP-9 INH.I)
administration on the effect of dynorphin A(1e17) in rats 7 days after
CCI
We observed that minocycline diminished the level of MMP-9 in
DYN-treated CCI-exposed rats (Table 1), therefore, we studied
whether the inhibition of MMP-9 will also reverse the neurotoxic
effects of high doses of DYN in the same experimental scheme. The
control group consisted of animals without sciatic nerve injury. The
reaction to mechanical stimuli (von Frey's test) was observed at
26.0 ± 0.7 g, and the reaction to low temperature was observed
after 27.3 ± 2.4 s (cold plate test). Reductions in the pain threshold
in animals with sciatic nerve ligationwere observed in the von Frey
test (12.5 g± 0.4; Fig. 3A) and the cold plate test (7.3 s± 0.7; Fig. 3B).
DYN (DYN, 15 nmol) caused ﬂaccid paralysis. The effect of DYN was
observed 30 min after DYN administration, and persisted for up to
24 h after administration (data not shown).
Repeated administrations of MMP-9 INH.I reduced allodynia
(11.0 g ± 0.4 vs.15.1 g ± 2.2; Fig. 3A) and hyperalgesia (5.8 s ± 0.4 vs.
14.0 s ± 2.1; Fig. 3B). An analgesic effect of MMP-9 INH.I was also
demonstrated after 24 h in the von Frey test (20.0 g ± 1.5) and the
cold plate test (15.1 s ± 1.7; data not shown).
Our results indicate that similarly to minocycline, a selective
inhibitor of MMP-9 exerts an analgesic effect in behavioral studies,
and its administration prevents the occurrence of ﬂaccid paralysis
caused by dynorphin administration.
4. Discussion
Numerous studies conﬁrm that nerve injury increases prody-
norphin mRNA, which correlates with the onset of neuropathic
pain symptoms (Kajander et al., 1990; Draisci et al., 1991; Malan
et al., 2000; Wang et al., 2001; Obara et al., 2003; Mika et al.,
2011). Studies of prodynorphin gene knock-out mice show that
animals normally respond to nociceptive stimuli, which suggests
that the role of dynorphin in nociception is primarily related to
pathological processes. A single intrathecal administration of
dynorphin causes long-lasting allodynia (Vanderah et al., 1996;
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Table 2
The inﬂuence of norBNI (13.6 nmol, a highly selective kappa-opioid antagonist) on the dynorphin (DYN) analgesic (0.15 nmol) or neurotoxic (15 nmol) effects on day 7
following sciatic nerve ligation (CCI). The results are presented as means ± SEM. The N group consisted of control naïve animals without sciatic nerve injury; the V þ V group
consisted of animals with sciatic nerve ligation receiving vehicle (V); the V þ DYN group consisted of animals with sciatic nerve ligation receiving a single dose of DYN; the
norBNI þ DYN group consisted of animals with sciatic nerve ligation receiving a single doses of norBNI and a single dose of DYN. Inter-group differences were analyzed by
ANOVA Bonferroni's Multiple Comparison Test: ***p < 0.001 indicates a signiﬁcant difference marked only between control (naïve rats) and vehicle-treated CCI-exposed rats;
#p < 0.05;###p < 0.001 vs. V þ V CCI-exposed; ^p < 0.05V þ DYN vs. norBNI þ DYN CCI-exposed; Vehicle (V; water for injection).
E. Rojewska et al. / Neuropharmacology 86 (2014) 301e310 307Laughlin et al., 1997), particularly at high doses. Typical pain-
related behaviors, such as gnawing or licking, were described
following the intrathecal administration of a high doses of DYN
(Tan-No et al., 2002). High doses of DYN (15e50 nmol) in rats were
also used as a model of neuropathic pain because they cause
neurotoxic effects and damage sensory neurons, motoneurons and
interneurons in the gray matter of the spinal cord (Herman et al.,
1980; Long et al., 1988). Therefore, elevated endogenous dynor-
phin leads to motor dysfunctions (Faden, 1990; Malan et al., 2000).
Our present studies showed that in contrast to the neurotoxic effect
of high doses of DYN, the intrathecal administration of a high dose
of U50,488H also attenuates allodynia and hyperalgesia. Moreover,
repeated administrations of minocycline, which reduce endoge-
nous dynorphin levels, enhance the analgesic effects of U50,488H,
which further conﬁrms that DYN exerts its toxic effects via mech-
anisms distinct from opioid receptor, possibly through the
involvement of glia cells besides NMDA receptor. Interestingly, our
studies demonstrated a complete blockade of ﬂaccid paralysis after
high-dose DYN administration in rats previously receiving mino-
cycline. These observations suggest beneﬁcial, neuroprotective ef-
fects of minocycline and also the importance of microglia in the
toxic effects of DYN. Minocycline has another important effect
beyond the inﬂuence on endogenous prodynorphin levels, as
shown by Machado et al. (2006), who provided evidence that
minocycline inhibits MMP-9 activity, which is increased in
ischemia. Minocycline in ischemic models inhibited inﬂammation,
microglial activation, apoptosis and the degradation of extracellular
matrices, i.e., it exerted neuroprotective effects (Tikka and
Koistinaho, 2001; Domercq and Matute, 2004). In 2001 Tikka and
Koistinaho have shown that minocycline prevented the NMDA-
induced activation and proliferation of microglia and diminished
the release of IL-1b in pure microglia cultures (Tikka and
Koistinaho, 2001). In 2007, we showed that minocycline exerted a
neuroprotective function, and it even accelerated nerve regenera-
tion (Mika et al., 2007). The data presented by Kawasaki et al.
(2008) suggest that MMP-9 inhibition is beneﬁcial for antago-
nizing neuropathic pain. Considering the role of MMP-9 and its
endogenous inhibitor TIMP-1 in the development of neuropathy,
this strong inhibitory effect of minocycline on MMP-9 mRNA
expression might be the cause of the analgesic and neuroprotectiveFig. 1. The effect of repeated intrathecal minocycline administration (MC, 60 mg/5 ml, 16 and 1
A(1e17) (DYN, 0.15 nmol and 15 nmol) and a combination of MC and DYN (MC þ DYN), a si
allodynia (A, C, E, G; von Frey test) and hyperalgesia (B, D, F, H; cold plate test), a single d
(MC þ norBNI) on day 7 following sciatic nerve ligation (CCI). The results are presented as m
control naïve animals without sciatic nerve injury; the V þ V group consisted of animals with
sciatic nerve ligation receiving MC; the V þ DYN/U50,488H/norBNI group consisted of anim
U50,488H/norBNI; the MC þ DYN/U50,488H/norBNI group consisted of animals with sciat
norBNI. Inter-group differences were analyzed by ANOVA Bonferroni's Multiple Comparison
rats) and vehicle-treated CCI-exposed rats; #p < 0.05, ##p < 0.01,###p < 0.001 vs. V þ V CCI-e
exposed rats; ^p < 0.05, ^^ ^p < 0.001 differences between V þ DYN/norBNI and MC þ DYN/effects. The intrathecal administration of the MMP-9 inhibitor
attenuated mechanical allodynia and thermal hyperalgesia in our
study, similar to minocycline administration. Our hypothesis was
conﬁrmed by our behavioral studies, which showed that intra-
thecal MMP-9 inhibitor administration prevented DYN-induced
ﬂaccid paralysis in a manner similar to minocycline.
The effects of minocycline on prodynorphin levels suggest an
important role of microglia in the neurotoxicity of this peptide.
Numerous literature data also suggest increased spinal IL-1bmRNA
levels following injury (Wang et al., 2005; Lyons et al., 2007; Mika
et al., 2008). Other authors have suggested that the analgesic effects
of minocycline during neuropathy are due to reduced IL-1b mRNA
and TNF-a expression in the spinal cord (Ledeboer et al., 2005; Piao
et al., 2006). Both pro- and anti-inﬂammatory cytokines play
important roles in nociceptive transmission and the regulation of
neuropathic pain, and therefore, we studied the most important
antinociceptive interleukins during neuropathic pain. Our experi-
ments also demonstrated a strong increase in IL-1a and IL-10mRNA
levels in the DRG following CCI, which is consistent with our pre-
vious ﬁndings (Mika et al., 2008), however minocycline adminis-
tration as well as dynorphin administration does not affect this
changes. Our results are consistent with those of Ledeboer et al.
(2005), who suggested that the analgesic effect of minocycline
was not due to an increased expression of anti-inﬂammatory but to
reduced levels of pro-inﬂammatory cytokines. The administration
of high doses of DYN in a neuropathic pain model does not increase
the already high level of the C1q-positive cells in the spinal cord
and DRG, but it strongly increases the expression of pro-
inﬂammatory cytokines IL-1b and IL-6 mRNA. Our data suggest
that DYN does not induce microglia activation, but it can polarize
microglia to an M1 type. Notably, our studies showed that intra-
thecal minocycline administration prevented DYN-induced ﬂaccid
paralysis and reduced the upregulation in IL-1b and IL-6 mRNA
levels in the spinal cord and DRG, which suggests that these cyto-
kines are responsible for the non-opioid adverse effects of
dynorphin.
In conclusion, our studies revealed a very signiﬁcant inﬂuence of
repeated intrathecal minocycline administration on the prodynor-
phin system in the pathomechanism of neuropathic pain. Mino-
cycline inhibited the development of ﬂaccid paralysis followingh before sciatic nerve injury and then once daily for 7 days), a single dose of dynorphin
ngle dose of U50,488H (U50,488H, 25 nmol and 100 nmol) and MC and U50,488H on
ose of norBNI (norBNI, 6.8 nmol and 13.6 nmol) and a combination of MC and norBNI
eans ± SEM; the horizontal dotted line shows the naive group. The N group consisted of
sciatic nerve ligation receiving vehicle (V); the MC þ V group consisted of animals with
als with sciatic nerve ligation receiving repeated doses of V and a single dose of DYN/
ic nerve ligation receiving repeated doses of MC and a single dose of DYN/U50,488H/
Test: ***p < 0.001 indicates a signiﬁcant difference marked only between control (naïve
xposed; &p < 0.05, &&&p < 0.001 differences between MC þ V and MC þ U50,488H CCI-
norBNI CCI-exposed rats. Vehicle (V; water for injection).
Fig. 2. The effect of repeated intrathecal minocycline administration (MC, 60 mg/5 ml, 16 and 1 h before sciatic nerve injury and then once daily for 7 days) on mRNA expression of
anti-inﬂammatory interleukins IL-1a and IL-10 and pro-inﬂammatory cytokines IL-1b and IL-6 on day 7 following sciatic nerve ligation (CCI) as measured in the spinal cord (A, C, E,
G) and DRG (B, D, F, H). The values were standardized against HPRT. The results are presented as fold changes of control (N); the horizontal dotted line shows the naive group. The N
group consisted of control naïve animals without sciatic nerve injury; the V þ V group consisted of animals with CCI receiving V; the MC þ V group consisted of animals with CCI
receiving MC; the V þ DYN group consisted of animals with CCI receiving a single dose of dynorphin A(1e17) (DYN); the MC þ DYN group consisted of animals with CCI receiving
repeated doses of MC and a single dose of DYN. Inter-group differences were analyzed by ANOVA Bonferroni's Multiple Comparison Test: *p < 0.05, ***p < 0.001 indicates a
signiﬁcant difference marked only between control (naïve rats) and vehicle-treated CCI-exposed rats; #p < 0.05, ###p < 0.001 vs. V þ V CCI-exposed; &&&p < 0.001 differences
between MC þ V and MC þ DYN CCI-exposed rats; ^p < 0.05, ^^ ^p < 0.001 differences between V þ DYN and MC þ DYN CCI-exposed rats. Vehicle (V; water for injection).
E. Rojewska et al. / Neuropharmacology 86 (2014) 301e310308high-dose (15 nmol) DYN administration in rats. Our study showed
that minocycline reduced prodynorphin and MMP-9 mRNA levels,
which were previously elevated following sciatic nerve injury in
the spinal cord and/or DRG. Additionally, minocycline prevented
the upregulation of IL-1b and IL-6mRNA following intrathecal DYNadministration (15 nmol). This beneﬁcial effect of minocycline can
be related to a signiﬁcant downregulation of MMP-9 mRNA, which
was also supported by our pharmacological results. We have
proven that a selective inhibitor of MMP-9 prevented ﬂaccid pa-
ralysis induced by DYN, similarly to minocycline. The results of the
Fig. 3. The effect of repeated administration of metalloproteinase-9 inhibitor I (MMP-9 INH.I; 5 mg/5 ml, 30 min before the behavioral tests on day 7 of neuropathic pain or 16 and 1 h
before sciatic nerve injury and then once daily for 7 days) on the effects of a single dose of dynorphin A (DYN, 15 nmol) as measured in the von Frey test (A) and cold plate test (B) on
day 7 following sciatic nerve ligation (CCI). The results are presented as fold changes of control (N); the horizontal dotted line shows the naive group. The N group consisted of
control animals without sciatic nerve injury; the V þ V group consisted of animals with sciatic nerve ligation receiving V; the MMP-9 INH.I þ V group consisted of animals with
sciatic nerve ligation receiving single or repeated doses of MMP-9 INH.I; the V þ DYN group consisted of animals with sciatic nerve ligation receiving a single dose of DYN; the
MMP-9 INH.I þ DYN group consisted of animals with sciatic nerve ligation receiving single doses of MMP-9 INH.I and DYN. Inter-group differences were analyzed by ANOVA
Bonferroni's Multiple Comparison Test: ***p < 0.001 indicates a signiﬁcant difference marked only between control (naïve rats) and vehicle-treated CCI-exposed rats; ###p < 0.001
vs. DMSO þ V CCI-exposed rats; &&&p < 0.001 differences between MMP-9 INH.I þ V vs. MMP-9 INH.I þ DYN CCI-exposed rats. Vehicle (V; DMSO).
E. Rojewska et al. / Neuropharmacology 86 (2014) 301e310 309present study shed new light on the mechanisms of action of
dynorphin and suggest possible ways to modulate its adverse
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